Source: Pharmacy Times articles
The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
Recent Content
- Patients and Caregivers Aim to Raise Funds for Myeloma Research
- GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
- Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
- Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
- Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
- Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
- Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
- Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
- Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus